Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Marco Russano

Clinical Outcomes of Patients With Advanced Cancer and Pre‐Existing Autoimmune Diseases Treated With Anti‐Programmed Death‐1 Immunotherapy: A Real‐World Transverse Study

Oncologist
Cancer ResearchMedicineOncology
2019English

Prognostic and Predictive Factors in Pancreatic Cancer

Oncotarget
Oncology
2020English

Related publications

P012 Patients With Cancer and Preexisting Autoimmune and Inflammatory Diseases Treated by Anti-Programmed Death 1 (PD-1) Antibodies at Gustave Roussy Cancer Center

2019English

Clinical Significance of Soluble Programmed Cell Death-1 and Soluble Programmed Cell Death-Ligand 1 in Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy

PLoS ONE
Multidisciplinary
2019English

Real‐World Outcomes of Patients With Metastatic Non‐Small Cell Lung Cancer Treated With Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval

Oncologist
Cancer ResearchMedicineOncology
2018English

Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy

JAMA Dermatology
DermatologyMedicine
2016English

Predictive Role of Computed Tomography Texture Analysis in Patients With Metastatic Urothelial Cancer Treated With Programmed Death-1 and Programmed Death-Ligand 1 Inhibitors

European urology oncology
OncologyRadiologyUrologyNuclear MedicineImagingSurgery
2019English

Outcomes by Line of Therapy and Programmed Death Ligand 1 Expression in Patients With Advanced Melanoma Treated With Pembrolizumab or Ipilimumab in KEYNOTE-006: A Randomised Clinical Trial

European Journal of Cancer
Cancer ResearchOncology
2018English

2241. Outcomes of Program Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(pd-L1) Inhibitor Therapy in HIV Patients With Advanced Cancer

Open Forum Infectious Diseases
OncologyNeurology
2018English

Recurrent Pneumonitis Induced by Atezolizumab (Anti–Programmed Death Ligand 1) in NSCLC Patients Who Previously Experienced Anti-Programmed Death 1 Immunotherapy-Related Pneumonitis

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Clinicopathological Features Predict Outcomes in Patients With Radioiodine‐Refractory Differentiated Thyroid Cancer Treated With Sorafenib: A Real‐World Study

Oncologist
Cancer ResearchMedicineOncology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy